Venkat AG, Arepalli S, Sharma S, et al. - In this Institutional Review Board-approved retrospective case series, researchers analyzed successful management of cancer therapy-associated uveitis with local therapy based on uveitis subtype. The study sample consisted of patients with uveitis secondary to immunotherapy or targeted therapy managed with local treatment and focused literature review. Participants in the study were five patients (median age: 54, range 31 to 75). Following cancer therapy initiation, time to uveitis onset was 3 to 12 months. Based on the series and existing literature demonstrating the use of local therapy for immune-related adverse events, the authors propose a local therapy approach for cancer therapy-associated uveitis starting with topical steroids and initiating injectable steroids in recalcitrant panuveitis or posterior uveitis cases. Subclinical inflammation of the posterior segment imagery is a robust response to difluprednate or intravitreal steroid treatment, and patients with posterior segment involvement may require more aggressive management and long-term maintenance. Patients with isolated anterior uveitis did not need maintenance topical therapy; chronic low-dose topical treatment was needed for those with posterior and panuveitis.